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A case report of vanishing bile duct syndrome after exposure to
pexidartinib (PLX3397) and paclitaxel
Sorbarikor Piawah1, Colby Hyland2, Sarah E. Umetsu3, Laura J. Esserman2, Hope S. Rugo1 and A. Jo Chien1
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy
designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-
Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation
due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized
neoadjuvant chemotherapy trial in patients with Stage II–III breast cancer. We also review the current literature on this rare,
idiosyncratic, and potentially life-threatening entity.
npj Breast Cancer            (2019) 5:17 ; https://doi.org/10.1038/s41523-019-0112-z
INTRODUCTION
Drug-induced liver injury (DILI) is a growing medical and public
health problem. With a worldwide estimated annual incidence of
1–2 severe cases per 1000–10,000 patients exposed, it is the most
common cause of acute liver failure in the United States.1,2
Because most new drugs are tested in fewer than 3000 people by
the time a new drug application is filed, cases of severe DILI are
usually discovered only after drug approval.
Here, we report a case of severe DILI requiring liver
transplantation after exposure to pexidartinib (PLX3397), an
oral agent used in one experimental arm of the I-SPY 2 platform
trial of neoadjuvant study for early breast cancer at high risk of
early recurrence (clinicaltrials.gov identifier NCT01042379).
Pexidartinib is a small molecule inhibitor of the c-kit tyrosine
kinase and colony-stimulating factor-1 (CSF-1) receptor kinase.3,4
CSF-1 has been linked to tumor growth and progression in
breast cancer,5,6 and has been shown to effectively reduce the
number of tumor-associated macrophages in different tumor
types.4,5
Pexidartinib was granted Breakthrough Therapy Designation by
the U.S. Food and Drug Administration (FDA) in 2015 for
tenosynovial giant-cell tumor (TGCT) based on phase 1 results
that showed significant response;4 it is currently under FDA review
for the treatment of TGCT based on a phase 3 registration study.7
Pexidartinib is also being evaluated in several other cancer types,
including refractory Hodgkin’s lymphoma (NCT01217229), glio-
blastoma multiforme (NCT01349036), and metastatic breast
cancer (NCT01596751). Studies have reported elevated amino-
transferases in ~50% of patients, generally considered to be a
consequence of CSF-1 pathway inhibition in Kupffer cells in the
liver, and the most common adverse effect of pexidartinib.4,8
Other reported toxicities include hair color changes, periorbital
edema, vomiting, fatigue, and dysgeusia.7
RESULTS
Patient history and presentation
The patient is a 62-year-old postmenopausal woman diagnosed
with a clinical stage 2B hormone receptor positive, HER2-negative
left breast cancer. Primary tumor was 3 cm with a 2.5–cm mobile
left axillary lymph node. She was otherwise healthy with no
significant past medical history. Reported medications included
vitamin D-3, citalopram, and zolpidem, and the patient denied use
of over-the-counter medications, including herbs and supple-
ments. On average, she reported consumption of seven glasses of
wine/week. Her BMI was 30. Baseline liver function tests (LFTs)
were in the normal range. Staging PET/CT showed no evidence of
distant metastasis.
The patient provided written informed consent prior to
screening and again prior to enrollment in the I-SPY 2 TRIAL,9–11
a trial testing agents in combination chemotherapy in the
neoadjuvant setting in patients with early breast cancer. The trial
was approved by the UCSF Institutional Review Board, and written
informed consent was obtained for publication of this case report.
The goal of neoadjuvant chemotherapy in the treatment of early-
stage breast cancer is to down-stage tumors, improve surgical
options, and to assess response to therapy which provides
valuable prognostic information. Patients in this multi-arm trial
are randomized to receive standard chemotherapy or standard
chemotherapy in combination with one of several experimental
agents. The patient was randomized to an investigational
treatment arm including weekly intravenous paclitaxel
(80 mg/m2) in combination with oral pexidartinib 1200mg daily
for 12 weeks. The dose of pexidartinib was selected based on
safety and efficacy data from a previously reported phase 1b trial
of pexidartinib and weekly paclitaxel in patients with advanced
solid tumors.12
Approximately 3 weeks after starting study therapy (3 doses of
weekly paclitaxel and 27 oral daily doses of pexidartinib), the
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patient was admitted for fever up to 103 °F. Initial laboratory
studies were notable only for mildly elevated transaminases (ALT
65 U/L, AST 105 U/L) with normal white blood cell count, alkaline
phosphatase (ALP), and total bilirubin (Tbili). The patient
discontinued all study therapy immediately.
Diagnostic workup
Infectious workup, including blood and urine cultures, viral panel,
and chest X-ray were unremarkable. The patient remained febrile
to 103.5 °F. LFTs continued to rise during the hospitalization, with
day 3 studies showing ALT 158 U/L, AST 188 U/L, ALP 119 U/L, and
Tbili 1.9 mg/dL (direct bilirubin 1.3 mg/dL). On hospital day (HD) 3,
an abdominal ultrasound showed evidence of gallbladder wall
thickening and trace peri-cholecystic fluid, but no evidence of
cholelithiasis or biliary ductal dilatation. Abdominal/pelvis CT scan
showed new diffuse heterogeneous enhancement of the liver with
periportal edema and marked gallbladder wall thickening.
Following the abdominal/pelvis CT scan, the patient was started
on broad spectrum antibiotics for empiric treatment of acalculous
cholecystitis. Hepatobiliary (HIDA) scan showed no focal perfusion
defects and was consistent with cholestasis and a high functional
obstruction of the common and cystic duct. Magnetic resonance
cholangiopancreatography (MRCP) revealed heterogeneous
enhancement of the liver without focal liver lesions. There was
no intra- or extrahepatic bile duct dilatation and no contrast
excretion into the biliary system.
The patient underwent laparoscopic cholecystectomy on HD 6.
An intraoperative cholangiogram was performed and did not
show significant filling defects, extravasation, or dilatation of the
visualized intra- and extrahepatic ducts. The final surgical
pathology was consistent with acute cholecystitis.
The LFTs continued to increase post cholecystectomy, with a
rise in bilirubin out of proportion to the rise in transaminases. On
HD10, ALT was 194 U/L, AST 250 U/L, ALP 377 U/L, and Tbili
10.9 mg/dL. Due to the continued steady rise in bilirubin, a
diagnostic endoscopic retrograde cholangiopancreatography
(ERCP) was performed on HD10, which revealed a cannulated
common bile duct and normal appearing bile duct on cholangio-
gram. The intrahepatic biliary tree was filled and appeared normal.
A liver core biopsy was performed on HD 11. The biopsy
revealed mild cholestasis with small and attenuated bile ducts and
focal duct loss. Representative images are shown in Fig. 1, along
with a normal liver biopsy for comparison. The portal tracts
contained minimal lymphocytic inflammation and no ductular
reaction. The lobules showed grade 3 small droplet steatosis
without ballooned hepatocytes or Mallory hyaline, and no
significant hepatocyte necrosis. In particular, there was no
evidence of malignancy. Trichrome stain showed no increased
fibrosis. Copper stain was negative, and iron showed 1+ staining
in hepatocytes. Overall the findings were of cholestasis with duct
damage, and duct loss (only three of eight portal tracts containing
ducts) (Fig. 1a). Based on these findings and the patient’s clinical
presentation, a diagnosis of acute drug-induced liver injury,
suggestive of vanishing bile duct syndrome (VBDS) was made,
most likely secondary to the experimental agent pexidartinib in
combination with paclitaxel.
Medical management and treatment
The patient was started on ursodiol 1200mg/day for progressive
pruritis on HD 12. Prednisone 40mg daily was started on HD 14,
and she was discharged to home on HD 15.
Following discharge, the patient was tapered off prednisone
over the course of 1 month. She was started on the aromatase
inhibitor, letrozole, 2 weeks after discharge from the hospital.
Despite initial improvement in transaminases and ALP, her Tbili
continued to rise and remained persistently elevated to a peak of
32.6, 5 months after discontinuation of pexidartinib. Six months
after starting letrozole, she underwent left mastectomy and
axillary lymph node dissection. Pathology revealed residual 2 -cm
grade 2 invasive ductal carcinoma with a cellularity of 5%. Notably,
Fig. 1 Histology. a Representative portal tract from the liver biopsy with absence of the interlobular bile duct. The hepatocytes show severe
small droplet steatosis. (H&E, ×400). b The explant liver showed a biliary pattern of cirrhosis with extensive ductular reaction (H&E, ×40). c A
portal tract from the liver explant with absence of the interlobular bile duct and associated ductular reaction and cholestasis (H&E, ×20). d
Example of normal portal tract
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20 axillary nodes were negative for carcinoma demonstrating an
excellent response to neoadjuvant systemic therapy.
Over the following 13 months, the patient’s LFTs remained
abnormal with ALT/AST 150–200 U/L, ALP 350–400 U/L, and Tbili
20–25mg/dL. During this time, her functional status deteriorated
due to progressive fatigue, anorexia, pruritis, and depression.
Greater than 50% of her time was spent in bed, and she lost 60
pounds. She remained on ursodiol and doxepin for pruritis, as well
as monthly vitamin K injections. Due to chronicity and severity of
her symptoms, the patient underwent orthotopic liver transplant
20 months after her initial diagnosis of severe DILI.
The liver explant showed cirrhosis with cholestasis, loss of
interlobular bile ducts, and extensive ductular reaction. Larger bile
ducts appeared intact without duct damage. No significant
steatosis was seen (grade 0). Overall, the findings were consistent
with ductopenia, likely secondary to drug-induced vanishing bile
duct syndrome (Fig. 1b, c).
Following transplantation, the patient’s LFTs and performance
status improved precipitously. She is currently on chronic
immunosuppression with everolimus and is thriving clinically
22 months post transplant. Her appetite and energy have
significantly improved, pruritis has resolved, and she is at a
healthy weight. She remains disease free from breast cancer on
adjuvant letrozole. The trend in her LFTs pre- and post transplant
are outlined in Fig. 2.
DISCUSSION
VBDS is a form of DILI that describes acquired disorders related to
the progressive destruction and disappearance of intrahepatic bile
ducts, leading to cholestasis.13 First described in 1988 in three
patients,14 VBDS is largely idiosyncratic, but has been causally
associated with a variety of etiologies, including genetic diseases
such as cystic fibrosis and Williams syndrome,15 neoplasms such as
lymphoma,16–18 immune disorders including graft-versus-host dis-
ease,15,19 viral infections,20–23 and most commonly, pharmaceuticals.
VBDS has been associated with numerous drug classes, including
antibiotics, non-steroidal anti-inflammatories, antipsychotics, anti-
epileptics, antihypertensives, diabetes medications,13,24–33 and oral
chemotherapy drugs such as temozolomide.30,31
In most instances, the ductopenia in VBDS preferentially affects
the smaller interlobular bile ducts rather than the larger bile ducts
that are usually destroyed in primary biliary cirrhosis. Defined as
the loss of >50% of interlobular ducts, or a bile duct to portal tract
ratio of <0.5,2,14,33–35 patients with VBDS commonly present with
jaundice, itching, fatigue, and anorexia.2,31,32 Laboratory
evaluation reveals cholestasis, including profound elevations in
ALP and gamma-glutamyl transferase, as well as high serum
concentrations of bilirubin, with relatively mild elevations in serum
aminotransferases.2 It is hypothesized that the bile duct injury
seen in VBDS is due to an inflammatory response directed at
cholangiocytes, which play an integral role in lining the lumen of
bile ducts, sealing the biliary epithelium, and bile formation.
Immune-mediated destruction of cholangiocytes results in pro-
longed cholestasis, bile duct degeneration, and loss of bile ducts.2
In the acute phase, histologically there may be evidence of
periportal mixed inflammatory infiltrates including neutrophils,
lymphocytes, and eosinophils, as well as cytoplasmic vacuolization
and swelling of cholangiocytes and ductular infiltration by
lymphocytes.2,35 As this inflammatory response diminishes follow-
ing discontinuation of the offending agent, in most cases
cholestasis improves. However, in a minority of patients, such as
ours, progressive bile duct loss becomes chronic and results in
liver transplant, or death.17,32,35
There are limited data regarding the optimal treatment for
VBDS. In general, treatment is supportive, focused on reducing
symptoms associated with prolonged cholestasis. Ursodeoxycholic
acid is a mainstay of therapy, and is thought to stimulate bile
secretion and promote survival of cholangiocytes by inhibiting the
intrinsic apoptosis pathway.2,36 Steroids and other immunosup-
pressants such as low-dose mycophenolate have been used
successfully, suggesting a potential benefit in targeting the
underlying inflammatory mechanisms described above.2,37
There are limited data regarding the prognosis of VBDS. Some
insight is provided by the Drug Induced Liver Injury Network
(DILIN) study. In this prospective study of 363 patients with a
diagnosis of DILI and a liver biopsy, 26 patients (7%) had evidence
of bile duct loss, consistent with VBDS.32 The time from starting
the implicated drug to onset of VBDS symptoms ranged from 3-
551 days. Patients with evidence of bile duct loss on biopsy were
more likely to develop cholestatic chronic liver injury (94 vs. 47%)
and had significantly higher mortality rates (27 vs. 9%) compared
with the 337 patients with DILI without evidence of VBDS.32 The
most significant predictor of a poor outcome, including death or
liver transplantation, was the degree of bile duct loss in the
diagnostic liver biopsy. Patients with poor outcomes had a lower
average percent of portal areas with bile ducts present compared
with patients with good outcomes (17 vs. 64%, respectively).
Laboratory tests at the time of injury were not predictive of
outcome.32
Here, we report VBDS and severe DILI associated with
pexidartinib, in this case, combined with weekly paclitaxel. Given
Fig. 2 Trends in hepatic enzyme and bilirubin levels in U/L from baseline through 6 months post-liver transplant. Aspartate aminotransferase
(AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) trends are shown on the primary y axis on the left. The total bilirubin (TBili)
trends are shown on the secondary y axis on the right
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the extensive existing safety data on paclitaxel (with cholestatic
jaundice infrequently reported),38 it is unlikely that paclitaxel was
the cause of this patient’s VBDS and severe DILI; however, it is
possible that paclitaxel played a role in combination with
pexidartinib. This incident is a reminder that close monitoring of
LFTs for patients enrolled on clinical trials is of critical importance,
as prior experience may not uncover these rare events. Some
cases of severe drug-induced DILI cannot be halted or reversed,
despite vigilance and early discontinuation of the offending agent
—it is worth noting that in this report, pexidartinib was
discontinued at the earliest sign of toxicity, yet cholestasis was
irreversible. As we continue to evaluate new targeted agents in
patients with potentially curable malignancies, it is critical that
safety be monitored in real time with immediate feedback to
reduce potentially life-threatening toxicities. Further evaluation of
these rare, idiosyncratic cases of severe DILI/VBDS will help
identify patients that may be at particular risk, and help improve
the prognosis for affected patients.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
Datasets that support the figures presented in this paper are available upon request,
as described at: https://doi.org/10.6084/m9.figshare.8089343.39
ACKNOWLEDGEMENTS
The I-SPY 2 Trial is supported by Quantum Leap Healthcare Collaborative (2013 to
present) and the Foundation for the National Institutes of Health (2010 to 2012) and
by grants from the National Cancer Institute Center for Biomedical Informatics and
Information Technology (2010-2012), as well as a number of private and public
foundations and donors. Plexxikon (Berkeley, CA) supplied pexidartinib (PLX3397)
free of charge along with some financial assistance. Plexxikon played no role in the
study design, data accrual, data analysis, or preparation of this paper.
AUTHOR CONTRIBUTIONS
A.J.C. was responsible for case management. A.J.C., S.P., C.H., H.R. and L.E. contributed
to case review. H.R. was responsible for safety monitoring. S.U. conducted the
pathological review. L.E. conceived, supervised and obtained funding for the I-SPY
2 study. A.J.C., S.P. and C.H. were the principal writers of the manuscript. S.U., H.R. and
L.E. edited and provided valuable insight in the preparation of the paper. All authors
approved the final paper.
ADDITIONAL INFORMATION
Supplementary Information accompanies the paper on the npj Breast Cancer
website (https://doi.org/10.1038/s41523-019-0112-z).
Competing interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Kullak-Ublick, G. A. et al. Drug-induced liver injury: recent advances in diagnosis
and risk assessment. Gut 66, 1154–1164 (2017).
2. Visentin, M., Lenggenhager, D., Gai, Z. & Kullak-Ublick, G. A. Drug-induced bile
duct injury. Biochim. Biophys. Acta 1864, 1498–1506 (2017).
3. Dammeijer, F. et al. Depletion of tumor-associated macrophages with a CSF-1R
kinase inhibitor enhances antitumor immunity and survival induced by DC
immunotherapy. Cancer Immunol. Res. 5, 535–546 (2017).
4. Tap, W. D. et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-
cell tumor. N. Engl. J. Med. 373, 428–437 (2015).
5. Shiao, S. L. et al. TH2-Polarized CD4(+) T cells and macrophages limit efficacy of
radiotherapy. Cancer Immunol. Res. 3, 518–525 (2015).
6. Achkova, D. & Maher, J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor
axis in cancer. Biochem. Soc. Trans. 44, 333–341 (2016).
7. Tap, W. D. et al. Final results of ENLIVEN: a global, double blind, randomized
placebo controlled phase 3 study of pexidartinib in advanced tenosynovial giant
cell tumor (TGCT). J. Clin. Oncol. 36 (Suppl); abstr, 11502 (2018).
8. Radi, Z. A. et al. Increased serum enzyme levels associated with kupffer cell
reduction with no signs of hepatic or skeletal muscle injury. Am. J. Pathol. 179,
240–247 (2011).
9. Carey, L. et al. I-SPY 2-toward more rapid progress in breat cancer treatment. N.
Engl. J. Med. 375, 83–84 (2016).
10. Park, J. et al. Adaptive randomization of neratinib in early breast cancer. N. Engl. J.
Med. 375, 11–22 (2016).
11. Rugo, H. et al. Adaptive randomization of veliparib-carboplatin treatment in
breast cancer. N. Engl. J. Med. 375, 23–24 (2016).
12. Rugo, H. et al. Phase 1b study of PLX3397, a CSF1R inhibitor, and paclitaxel in
patients with advanced solid tumors. Ann. Oncol. 25(suppl_4), iv148 (2014).
13. Nakanuma, Y., Tsuneyama, K. & Harada, K. Pathology and pathogenesis of
intrahepatic bile duct loss. J. Hepatobiliary. Pancreat. Surg. 8, 303–315 (2001).
14. Ludwig, J., Wiesner, R. H. & LaRusso, N. F. Idiopathic adulthood ductopenia. A
cause of chronic cholestatic liver disease and biliary cirrhosis. J. Hepatol. 7,
193–199 (1988).
15. Reau, N. S. & Jensen, D. M. Vanishing bile duct syndrome. Clin. Liver Dis. 12,
203–217 (2008).
16. Bakhit, M. et al. Vanishing bile duct syndrome in Hodgkin’s lymphoma: a single
center experience and clinical pearls. J. Clin. Gastroenterol. 50, 688 (2016).
17. Bakhit, M. et al. Vanishing bile duct syndrome in Hodgkin’s lymphoma: a case
report and literature review. World J. Gastroenterol. 23, 366–372 (2017).
18. Gill, R. M. & Ferrell, L. D. Vanishing bile duct syndrome associated with peripheral
T cell lymphoma, not otherwise specified, arising in a posttransplant setting.
Hepatology 51, 1856–1857 (2010).
19. Yeh, K. H. et al. Severe isolated acute hepatic graft-versus-host disease with
vanishing bile duct syndrome. Bone Marrow Transplant. 14, 319–321 (1994).
20. Oppenheimer, A. P. et al. Vanishing bile duct syndrome in human immunodefi-
ciency virus infected adults: a report of two cases. World J. Gastroenterol. 19,
115–121 (2013).
21. Hoffmann, R. M. et al. Hepatitis C virus infection as a possible risk factor for
ductopenic rejection (vanishing bile duct syndrome) after liver transplantation.
Transpl. Int. 8, 353–359 (1995).
22. Kikuchi, K. et al. Vanishing bile duct syndrome associated with chronic EBV
infection. Dig. Dis. Sci. 45, 160–165 (2000).
23. Tyagi, I. et al. Co-occurrence of cytomegalovirus-induced vanishing bile duct
syndrome with papillary stenosis in HIV infection. Hepatol. Res. 43, 311–314
(2013).
24. Basturk, A., Artan, R., Yilmaz, A., Gelen, M. T. & Duman, O. Acute vanishing bile
duct syndrome after the use of ibuprofen. Arab J. Gastroenterol. 17, 137–139
(2016).
25. Orman, E. S. et al. Clinical and histopathologic features of fluoroquinolone-
induced liver injury. Clin. Gastroenterol. Hepatol. 9, 517–523.e3 (2011).
26. Dousset, B., Conti, F., Houssin, D. & Calmus, Y. Acute vanishing bile duct syndrome
after interferon therapy for recurrent HCV infection in liver-transplant recipients.
New Engl. J. Med. 330, 1160–1161 (1994).
27. Juricic, D. et al. Vanishing bile duct syndrome associated with azithromycin in a
62-year-old man. Basic Clin. Pharmacol. Toxicol. 106, 62–65 (2010).
28. Robinson, W., Habr, F., Manlolo, J. & Bhattacharya, B. Moxifloxacin associated
vanishing bile duct syndrome. J. Clin. Gastroenterol. 44, 72–73 (2010).
29. Schumaker, A. L. & Okulicz, J. F. Meropenem-induced vanishing bile duct syn-
drome. Pharmacotherapy 30, 953 (2010).
30. Balakrishnan, A., Ledford, R. & Jaglal, M. Temozolomide-induced biliary ducto-
penia: a case report. J. Med. Case Rep. 10, 33 (2016).
31. Mason, M., Adeyi, O., Fung, S. & Millar, B.-A. Vanishing bile duct syndrome in the
context of concurrent temozolomide for glioblastoma. BMJ Case Rep. 2014, 1–4
(2014).
32. Bonkovsky, H. L. et al. Clinical presentations and outcomes of bile duct loss
caused by drugs and herbal and dietary supplements. Hepatology 65, 1267–1277
(2017).
33. Zhao, Z. et al. Acute vanishing bile duct syndrome after therapy with cephalos-
porin, metronidazole, and clotrimazole: a case report. Med. (Baltim.). 96, e8009
(2017).
34. Desmet, V. J. Vanishing bile duct syndrome in drug-induced liver disease. J.
Hepatol. 26(Suppl 1), 31–35 (1997).
35. Ramos, A. M. O. et al. Reversible vanishing bile duct syndrome induced by car-
bamazepine. Eur. J. Gastroenterol. Hepatol. 14, 1019–1022 (2002).
36. O’Brien, C. B., Shields, D. S., Saul, S. H. & Reddy, K. R. Drug-induced vanishing bile
duct syndrome: response to ursodiol. Am. J. Gastroenterol. 91, 1456–1457 (1996).
S. Piawah et al.
4
npj Breast Cancer (2019)    17 Published in partnership with the Breast Cancer Research Foundation
37. Tajiri, H., Etani, Y., Mushiake, S., Ozono, K. & Nakayama, M. A favorable response to
steroid therapy in a child with drug-associated acute vanishing bile duct syn-
drome and skin disorder. J. Paediatr. Child Health 44, 234–236 (2008).
38. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G. & Donehower, R. C. Clinical
toxicities encountered with paclitaxel (Taxol). Semin Oncol. 20(4 Suppl 3), 1–15 (1993).
39. Piawah, S. et al. Metadata supporting data files on “A case report of vanishing bile
duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel”. figshare.
https://doi.org/10.6084/m9.figshare.8089343 (2019).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
S. Piawah et al.
5
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2019)    17 
